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Medicine and Surgery, Federico II University. PAbstract Background and aims: Recent studies show that obesity is a risk factor for hospital
admission and for critical care need in patients with coronavirus disease 2019 (COVID-19). The
aim was to determine whether obesity is a risk factor for unfavourable health outcomes in pa-
tients affected by COVID-19 admitted to ICU.
Methods and results: 95 consecutive patients with COVID-19 (78 males and 18 females) were
admitted to ICU and included in the study. Height, weight, BMI, Sequential Organ Failure Assess-
ment (SOFA) and Acute Physiology and Chronic Health Evaluation II (APACHE II) scores, CRP, CPK,
ICU and hospital length of stay and comorbidities were evaluated. Participants with obesity had a
lower 28 day survival rate from ICU admission than normal weight subjects. Cox proportional
hazard model-derived estimates, adjusted for age, gender and comorbidity, confirmed the results
of the survival analysis (HR:5.30,95%C.I.1.26e22.34). Obese subjects showed longer hospital and
ICU stay as compared with normal weight counterpart.Subjects with obesity showed signifi-
cantly higher CRP and CPK levels than normal weight subjects.
Conclusion: In individuals with obesity, careful management and prompt intervention in case of
suspected SARS-CoV-2 infection is necessary to prevent the progression of the disease towards
severe outcomes and the increase of hospital treatment costs.
ª 2020 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Ital-
ian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II
University. Published by Elsevier B.V. All rights reserved.Introduction
Coronavirus disease 2019 (COVID-19), caused by SARS-
CoV-2 infection, includes a spectrum of illness; from
asymptomatic infection [1] to severe pneumonia charac-
terized by acute respiratory injury in about 20% of patients
presented for medical care [2]. The risk factors associatedof Medicine, Division of Geri-
Maggiore, Piazzale Stefani 1,
43.
.it (A.P. Rossi).
al., Obesity as a risk factor for un
lar Diseases, https://doi.org/10.1
, the Italian Society for the Study of Athe
ublished by Elsevier B.V. All rights reservewith disease severity included increased age, diabetes,
immune suppression and organ failure [2].
Preliminary studies in China, where SARS-CoV-2
initially spread, showed that obesity, especially in men,
significantly increased the risk of developing severe
pneumonia in infected patients.
Among 383 COVID-19 patients from Shenzhen, over-
weight was associated with an 86% higher, and obesity
with a 142% higher, risk of developing severe pneumonia
than patients of normal weight, when using statistical
models that controlled for potential confounders [3].favourable outcomes in critically ill patients affected by Covid 19,
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2 A.P. Rossi et al.Recent studies showed that obesity is a risk factor for
hospital admission and critical care need [4,5].
In particular Petrilli et al. [4] showed a significantly
strong association between older age, obesity, heart failure
and chronic kidney disease with hospitalization risk, with
much less influence of race, smoking status, chronic pul-
monary disease and other forms of heart disease. More-
over they found that the chronic condition with the
strongest association with critical illness was obesity, with
a odds ratio of 4.3 for BMI between 30 and 40/m2, and of
6.3 for BMI >40 kg/m2, even higher than any cardiovas-
cular or pulmonary disease.
Similar results were obtained by Lighter et al. in a pop-
ulation of patients aged <60 years, generally considered a
lower risk group for COVID-19 disease severity, confirming
that obesity appears to be a previously unrecognized risk
factor for hospital admission and critical care need [5].
This has important and practical implications, as nearly
40% of US adults and 21% of European ones are obese with
a BMI >30 [6e8]. Obesity in people <60 years of age is a
newly identified epidemiologic risk factor which may
contribute to the increased morbidity rates that are
experienced in the US [6].
Recent wide population studies from China [2] and
from the Lombardy region of Italy [9] that have reported
comorbidities in COVID-19 patients unfortunately did not
provide any data on body weight and height, which are
used to estimate adipose tissue mass by calculating the
BMI.
A descriptive study of a small sample of 24 (63% were
men) critically ill patients diagnosed with COVID-19 in the
Seattle region was among the first to report BMI data (3
patients with a BMI in the normal category, 7 with over-
weight, 13 with obesity and 1 with missing data). Although
the numbers are too small for meaningful statistical ana-
lyses, 85% of the patients with obesity required mechanical
ventilation and 62% of the patients with obesity died.
These proportions are greater than those in patients
without obesity, in which 64% required mechanical venti-
lation and 36% died [10]. These results are in line with
Simonnet et al. that observed an increased need for inva-
sive mechanical ventilation in subjects with BMI 35 kg/
m2 and Williamson reporting increased death risk in
subjects in 17 million adults from the NHS [11,12].
Obesity is a risk factor for hospital admission and for
critical care need [13], but only a few studies have inves-
tigated intensive care unit (ICU) main outcomes [10,12,14].
The primary aim of the present study was to evaluate if
obesity is a risk factor for unfavourable health outcomes in
critically ill COVID-19 patients to our ICUs.
The secondary aim was to compare, in different BMI
groups, the observed trend of CRP and CPK, as potential
clues of the pathophysiological mechanisms linking dis-
ease severity with BMI.
Methods
The study population consisted of 95 COVID-19 patients
from the REINSURE-ARDS registry (62.46  11.81 years;Please cite this article as: Rossi AP et al., Obesity as a risk factor for un
Nutrition, Metabolism & Cardiovascular Diseases, https://doi.org/10.1with mean BMI 29.20  3.49 kg/m2, 17 women), consec-
utively admitted to the ICU of the University Hospital In-
tegrated Trust of Verona between March 8th and March
30th, 2020. All subjects had microbiologic confirmation of
COVID-19 diagnosis by sampling of oro/nasopharyngeal
swab. Data was recorded by the attending physician team
reviewing medical charts, radiologic and laboratory re-
cords. Upper respiratory specimens were obtained in
accordance with the WHO indications [15], while venous
blood sampling was drawn in agreement with the current
guidelines [16].
This study was approved by the ethical board of the
University of Verona (Prog 1946CESC, Prot 72485 12/11/
2018). Patient identification remained anonymous and
written informed consent was obtained for participants.
All tests and procedures were performed in accordance
with the internal standards of care.
The ICU admission criteria and treatment decisions,
including the determination of the need for intubation and
type of administered antibiotic and antiviral therapy, were
not standardized and were made by the attending medical
team.
To determine the severity of illness upon ICU admis-
sion, the Acute Physiology And Chronic Health Evaluation
(APACHE) II score [17] was determined in all patients
within 24 h of ICU admission. In addition, organ failure
was assessed using the Sequential Organ Failure Assess-
ment (SOFA) scoring system [18].
Anthropometric measures
Patients’ height and weight were recorded at the begin-
ning of hospitalization as previously reported [19]. Body
mass index (BMI) was calculated as the ratio between
weight and height squared (kg/m2). The study population
was divided on the basis of BMI in normal weight subjects
(BMI<27 kg/m2), overweight (BMI between 27 and
29.9 kg/m2) and subjects with obesity (BMI30).
Biochemical measures
Repeated venous blood samples for C-reactive protein
(CRP) and creatin phosphokinase (CPK) levels were ob-
tained after overnight fasting.
For the measurement of CRP a kit was used for the
quantitative determination of CRP in serum (CRP ROCHE
applied on ROCHE/HITACHI COBAS 702, Roche Diagnostics
GmbH, Mannheim, Germany). Measurement uncertainty
declared 5.8%. The coefficient of variation (CV) of annual
CQI to 6 mg/L is 6%.
Creatine phosphokinase (CPK) concentration was
determined on a fully automated analyser ANALIZER
ROCHE/HITACHI COBAS 702 (Roche Diagnostics GmbH,
Mannheim, Germany). A multicenter evaluation of the
within-run precision of the Advia 2120 system showed CV
always lower than 0.7% for CPK.
Procalcitonin concentration were determined on the
fully automated analyser ANALIZER ROCHE/HITACHI COBAS
801 (Roche Diagnostics GmbH, Mannheim, Germany). Afavourable outcomes in critically ill patients affected by Covid 19,
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Obesity in critically ill patients with Covid 19 3multicenter evaluation of the within-run precision of the
ROCHE/HITACHI COBAS 801 system showed CV always
lower than 1.8% for PCT.
D-dimer concentration were determined on the fully
automated analyser ANALIZER ACL TOP 700 (Roche Di-
agnostics GmbH, Mannheim, Germany). A multicenter
evaluation of the within-run precision of the Advia 2120
system showed CV of 2% for D-dimer.
Further routine variables, such as sodium, potassium,
creatinine and white blood cells where also collected at
ICU admission and reported.Study outcomes
Our primary outcome (goal) was to assess if obesity is
associated with mortality, ICU length of stay (LOS) and
hospital LOS. Our secondary outcome (goal) was to assess
if obesity condition can influence the trend of inflamma-
tion as evaluated with CRP and critically ill induced
myopathy as evaluated with CPK.Statistical analysis
Results are shown as mean  SD. Variables not normally
distributed were log-transformed before analysis. Discrete
variables are expressed as counts (percentage) and
continuous variables as means  standard deviation (SD).
For the demographic and clinical characteristics of the
patients, differences between groups were assessed using
the chi-squared test and Fisher's exact test for categorical
variables and the Student's t-test or ManneWhitney U test
for continuous variables. Differences in mortality rates
across the three groups of participants were preliminarily
evaluated fitting KaplaneMeier survival curves adjusted
for age. Cox proportional hazard models and logistic
regression models were used to assess the risk of death.
Hazard Ratio (HR) and 95% Confidence intervals (95%
C.I.) were estimated to investigate the association of the
three study groups with the risk of mortality. Three
models were fitted for each outcome: unadjusted, age and
gender adjusted and adjusted for all potential con-
founders. Candidate variables to be included in the third
model were selected on the basis of the biological and
clinical plausibility as risk factors for mortality (age, sex,
smoking status, coronary heart disease, congestive heart
failure, hypertension, diabetes, neurological pathology,
chronic obstructive pulmonary disease, chronic renal fail-
ure, immunodepression and cancer). Additional models
such as interaction terms BMI x age and BMI x sex were
also included.
Students t-test for impaired data was used to compare
the trend of different biochemical variables between
normal weight subjects, overweight and subjects with
obesity.
The BMI value associated with higher mortality was
evaluated by means of the receiver operating characteris-
tics (ROC) curve, and was obtained by plotting estimates of
the true positive rate (i.e. sensitivity) against the falsePlease cite this article as: Rossi AP et al., Obesity as a risk factor for un
Nutrition, Metabolism & Cardiovascular Diseases, https://doi.org/10.1positive rate (1-specificity) for each possible BMI value.
Youden's index was then calculated.
A p-value of 0.05 or less was considered to be statisti-
cally significant.
Data analysis was conducted using SPSS 22.0 software
(Chicago, IL, USA) [20].
Results
Table 1 shows the main characteristics of the study pop-
ulation (mean  SD) at baseline, divided in normal weight,
overweight and subjects with obesity. 95 subjects, 78 men
and 17 women (17.9%) were included in the study.
All patients were COVID-19 positive as confirmed by
Nasopharyngeal-swab specimens which were performed
before or within the first 6 h of ICU stay.
As regards therapy all the patients received hydroxy-
chloroquine. Eighty-seven patients (92%) received lopina-
vir/ritonavir, while 8 patients (8%) were treated with
remdesivir. Tocilizumab was administered to 20 patients
(21%).
Mean delay between the onset of symptoms and hos-
pital admission was 3.87  2.2 days and between hospital
and ICU admission was 2.15  2.37 days.
The mean APACHE II score was 23.47  9.96 and the
mean SOFA score pre-intubation was 5.94  2.38. 91 out of
95 subjects required invasive mechanical ventilation. The
most common comorbidities were hypertension (47.4.%),
followed by heart disease (38.9%), obesity (35.78%) and
diabetes (18.95%).
Eighteen patients (18.9%) died during the first 28 days
since ICU admission. The mean CPK level adjusted for
weight at admission and on day 2 was significantly higher
in subjects who died than in survivors.
Fig. 1 shows that participants with obesity had the
shorter survival at 28 days from ICU admission as
compared to normal weight subjects. Estimates derived
from the Cox proportional hazard models (Table 2),
adjusted for age, gender and comorbidity, confirmed the
results of the survival analysis (HR 5.30, 95%C.I.
1.26e22.34). On the contrary overweight was not associ-
ated with increased risk. In the full adjusted model age
was independently associated with mortality (HR 1.13, 95%
C.I 1.05e1.21).
In an alternative model, in which the interaction term
BMI x age was added, the interaction term, was not
significantly associated with mortality (OR 1.01 [95%CI:
0.99e1.03]).
Similarly, when the interaction term BMI x sex was
added, both BMI and the interaction term were signifi-
cantly associated with mortality (OR 1.34 [95%CI:
1.14e1.57] and 1.55 [95%CI: 1.081e2.215], respectively).
After excluding individuals who died in the first 28 days
since ICU admission, obese subjects showed longer hos-
pital and intensive care stay as compared with normal
weight counterpart.
From day 5 to day 8 CRP values were significantly
higher in the group of subjects with obesity as compared
with the normal weight counterpart (Fig. 2A).favourable outcomes in critically ill patients affected by Covid 19,
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Table 1 Baseline demographic, anthropometric and clinical characteristics in different BMI groups (females, n Z 78; males, n Z 18).
Normal weight (n Z 28) Overweight (n Z 33) Obese (n Z 34) P
Mean  SD Min-Max Mean  SD Min-Max Mean  SD Min-Max
Age (years) 63.18  12.86 (29e80) 61.97  12.77 (33e82) 62.35  10.16 (37e86) NS
Sex (male) n (%) 24 (86%) 29 (88%) 25 (74%) NS
Height (m) 1.74  0.09 (1,62e1.96) 1.72  0.08 (1.4e1.86) 1.71  0.07 (1.58e1.84) NS
Weight (Kg) 76.48  9.69 (56e92) 86.29  8.28a (57e103) 95.79  8.71a (77e112) <0.001
BMI (Kg/m2) 25.21  1.66 (20.82e26.99) 28.87  0.79a (27.16e29.98) 32.81  2.20a (30.08e40.46) <0.001
CRP (mg/dL) 150.29  111.18 (19e410) 122.73  71.96 (30e290) 146.88  75.23 (6e298) NS
PCT (ng/mL) 6.94  26.91 (0.06e143) 0.72  1.02 (0.03e5.14) 0.58  1.07 (0.05e6.27) NS
D-Dimer (ng/mL) 2484.69  3147.00 (120e10,000) 1507.47  1525.41 (0e6773) 1595.67  1487.38 (330e6999) NS
CPK (U/L) 158.59  201.40 (0e840) 282  254.76a (27e954) 310.39  389.18 (24e1750) NS
Sodium (mmol/L) 137.36  2.97 (132e145) 137.18  5.71 (128e152) 136.41  4.50 (121e144) NS
Potassium (mmol/L) 3.82  0.48 (2.92e5.23) 3.80  0.42 (3.08e4.8) 3.85  0.43 (3.08e4.84) NS
Creatinine (mg/dL) 1.18  1.02 (0.56e5.67) 0.97  0.35 (0.47e1.93) 0.87  0.34 (0e1.91) NS
WBC (10̂6/mL) 9.01  4.36 (3.44e21.03) 8.47  3.16 (2.98e14.53) 8.51  3.78 (2.4e21.71) NS
SOFA preIOT 5.82  2.52 (3e11) 5.7  2.11 (3e10) 6.26  2.54 (3e14) NS
APACHE II 22.54  9.70 (7e47) 24.09  11.10 (8e44) 23.64  9.20 (8e53) NS
LOS ICU (days) 14.46  9.47 (1e32) 13.58  8.47 (3e40) 18.29  12.31 (1e40) NS
LOS Hospital (days) 23.61  10.05 (2e40) 22.88  9.70 (4e40) 26.59  12.7 (4e43) NS
Hypertension 10 (35.71%) 17 (51.51%) 17 (0.5) NS
Hearth Failure 2 (7.14%) 1 (3.03%) 1 (2.94%) NS
IHD 1 (3.57%) 0 (0%) 0 (0%) NS
Neurological disease 0 (0%) 0 (0%) 1 (2.94%) NS
Type 2 diabetes 2 (7.14%) 3 (9.09%) 13 (38.24%)a 0.002
Dyslipidemia 0 (0%) 1 (3.03%) 1 (2.94%) NS
Immunodepression 8 (28.57%) 3 (9.09%) 8 (23.53%) NS
CKD 5 (17.86%) 1 (3.03%) 9 (26.47%) 0.045
Cancer 1 (3.57%) 1 (3.03%) 1 (2.94%) NS
a p < 0.05.
4 A.P. Rossi et al.Subjects with obesity showed significantly higher CPK
values from day 7 and day 8 and overweight higher values
at admission, day 4 and day 5 as compared with normal
weight subjects, even after adjustment for body weight
(Fig. 2B). The threshold for BMI associated with a higher
risk of mortality in ICU was calculated locating the point
on the ROC curve that maximizes the sum of sensitivity
and specificity (i.e. Youden's index). This cutoff associated
with sensitivity of 0.611 and specificity of 0.519 was
29.23 kg/m2.Discussion
Our study shows that in COVID-19 critically ill subject
obesity (BMI30) is associated with a 5 times higher risk
of mortality and longer hospital stay. During the first 7
days in ICU subjects with obesity showed increased CRP
and CPK levels as compared with normal weight subjects.
Our result that patients with obesity are at higher risk
of death as compare with normal weight is in line with
Fezeu et al. and Louie et al. showing that severe obesity
resulted in a two-time greater risk of death upon influenza
A virus infection and hospitalization due to the infection,
with moderate obesity also increasing the risks [21,22].
When the study population was further divided ac-
cording to BMI categories (normal weight, overweight and
obese), subjects with obesity showed higher hospital and
ICU length of stay.Please cite this article as: Rossi AP et al., Obesity as a risk factor for un
Nutrition, Metabolism & Cardiovascular Diseases, https://doi.org/10.1Previous reports on hospitalized patients observed that
higher BMI is associated with increased morbidity and LOS
[23,24], which is one of the major determinants of hospital
costs [25].
We found that subjects with obesity have a longer ICU
stay than those with normal weight.
This confirms previous studies showing that in H1N1
influenza A virus pandemic in 2009 obesity increased both
the length of ICU stay and the need for mechanical
ventilation [26].
Preliminary reports on SARS-CoV-2 spread showed that
obese subjects are at greater risk for ICU admission and
invasive mechanical ventilation [27], but the potential
mechanisms that explain why obesity is associated with
increased COVID-19 severity have not been determined.
We found that during the first week in ICU, CRP levels
were higher in subjects with obesity when compared with
normal weight subjects. COVID-19 is characterized by a
reduction of T-Lymphocytes, involving in particular CD4þ
and CD8þ lines with concomitant 4 times increased
mortality when CD8þ level is below 75 cells/uL [28]. De
Biasi et al. [28] recently showed that Covid-19 is charac-
terized by a “cytokine storm” with increase in TNF-alfa,
CCL4, CD 27, CD 40, IL-2, IL-4, IL-7, IL 8, IL-10, IL-15, Il-
17A, but the greatest increase compared to controls has
been observed for IL-6. Obesity is associated with a state of
low grade chronic inflammation that contributes to the
onset of metabolic disease, type 2 diabetes, and dyslipi-
demia in particular and can determine a dampenedfavourable outcomes in critically ill patients affected by Covid 19,
016/j.numecd.2020.11.012
Figure 1 KaplaneMeier survival curves for all-cause mortality according to BMI groups, normal weight, overweight and obese. BMI: body mass
index.
Table 2 Mortality Risk According to BMI groups, using normal weight as Reference Group.
N of participants Events (%) Model 1 (unadjusted) Model 2 (Age and sex adjusted) Model 3 (Fully adjusteda)
HR C.I. (95%) HR C.I. (95%) HR C.I. (95%)
Normal weight 28 4 (14.3) 1 e 1 e 1 e
Overweight 32 5 (15.6) 1.13 0.30e4.22 1.37 0.36e5.21 1.42 0.32e6.28
Obese 35 9 (25.7) 1.99 0.61e6.49 3.47 1.00e12.03 5.30 1.26e22.34
HR: hazard ratio.
a Adjusted for age, sex, smoking habit, hypertension, diabetes, congestive heart failure, chronic renal failure, immunodepression, cancer,
chronic obstructive pulmonary disease, coronary heart disease.
Obesity in critically ill patients with Covid 19 5immune response to infectious agents, leading to poorer
outcomes post-infection [29,30].
Obesity has been also associated with higher circulating
IL-6 and CRP levels [25,26]. Adipose tissue, in particular
visceral fat, has been recognized to be able to secrete great
amounts of inflammatory cytokines [31].Figure 2 Changes during the first 7 days from admission in ICU in CRP leve
b p < .01.
Please cite this article as: Rossi AP et al., Obesity as a risk factor for un
Nutrition, Metabolism & Cardiovascular Diseases, https://doi.org/10.1Therefore, together, SARS-CoV-2 infection and obesity
may lead to a dysregulated immune response and
increased viral shedding, which could impact the outcome
of COVID-19 patients [32].
In both, human and murine models, it has been shown
that obese subjects present increased viral replicationl (Panel A) and CPK level (Panel B) across different BMI groups. a p < .05,
favourable outcomes in critically ill patients affected by Covid 19,
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6 A.P. Rossi et al.process, respiratory epithelium damage, pulmonary
oedema, increased inflammatory response, immunopa-
thology and poor wound recovery as compared with lean
subjects, resulting in increased mortality [33,34]. Although
there are still many unanswered questions regarding the
pathogenesis of COVID-19 pulmonary complications, a
central role of adipose tissue in the dysregulation of the
immune system can be hypothesized.
Adipocytes and adipocyte like cells, such as pulmonary
lipofibroblasts, may play a role in the pathogenetic
response to SARS-COV2 and be responsible for the exten-
sive pulmonary fibrosis and hypercoagulopathy observed
in COVID-19 patients [31,35,36].
Normal weight and obese subjects showed similar trend
in CPK level in the first 5 days from admission to ICU, but
interestingly subjects with obesity showed higher levels at
day 6 and 7 as compared with subjects with BMI<27.
An elevation in the serum CPK levels correlates with the
extent of muscular damage and is frequently observed in a
mixed ICU population [37]. Although usually asymptom-
atic, it could evolve into a life-threatening condition of
rhabdomyolysis complicated by acute renal failure and/or
disseminated intravascular coagulation [38].
In ICU unexplained CPK elevation is frequently
observed in medical or infectious disease patients and
elevated levels are observed in parallel with rise in LOS,
independently from the APACHE II score [39].
COVID-19-associated myopathy with severe proximal
and bulbar weakness, characterized by elevated levels of
IL-6 and CPK, histological perivascular inflammatory
infiltration with endomysial extension, muscle damage
and regenerating fibers has been reported [40].
It could be hypothesized that this histopathological
feature, associated with significant deficit of the upper and
lower limbs can be determined by the exaggerated in-
flammatory response observed in patients with COVID-19
and that in subjects with obesity this phenomenon can be
even more relevant, leading to worse clinical outcomes
and higher mortality, as shown in our study population. In
fact, obesity is associated with increased muscle vulnera-
bility, characterized by higher levels of myostatin, IL-6 and
macrophages, interfering with satellite cell activation and
myoblast proliferation and differentiation, which are
necessary steps for the muscle repair process after COVID-
19-induced muscle injury [41,42].
Moreover obesity is characterized by an increase of lipid
fat deposition between muscle fibers, the so-called inter-
muscular adipose tissue. This fat depot is a metabolically
active tissue, capable of secreting inflammatory cytokines,
increasing ceramides content and contributing to muscle
damage in paracrine manner [43,44]. We can theorize that
the close proximity to muscle fibers may impair the local
muscle environment, leading to an impairment of muscle
regeneration, also in critically ill COVID-19 patients.
CPK elevation observed in subjects with obesity could
be a sign of muscle injury and partially explains the
increased risk for ICU mortality and LOS observed in our
population. In fact, patients with high CPK levels are more
likely to receive invasive treatment in the ICU, so theirPlease cite this article as: Rossi AP et al., Obesity as a risk factor for un
Nutrition, Metabolism & Cardiovascular Diseases, https://doi.org/10.1muscle mass and strength may decrease with increasing
ICU stay [37] and are less likely to be discharged home,
because of hospital related independence loss. Further
investigation of the true incidence, complication rate and
independent risk factors for elevated CPK might be
warranted.
Some limitations need to be mentioned. Firstly this is a
single center observational prospective study. Secondly a
limited number of subjects were enrolled, with few
younger patients and very few older (very old) subjects.
The study sample size precludes meaningful explora-
tion of the association of wasting with specific disease
entities.
Thirdly, we used CRP as a nonspecific marker of
inflammation. It is known that CRP responds relatively
slowly to inflammatory stimuli and can be influenced by
liver function, given that it is hepatically synthesized.
Although strictly regulated by cytokines, mostly IL-6 and
TNF-alfa [45,46], once daily CRP measurement has limited
capacity to define the nature, cause, and scale of global and
sustained inflammatory load. Further studies evaluating
IL-6, TNF-alfa and adipokines should be conducted in order
to better understand the pathogenetic link between
obesity and unfavourable ICU health outcomes.
Last, BMI is a surrogate of total adiposity and to better
understand the role of adipose tissue on COVID-19
severity, studies evaluating body fat distribution and
consequent organ fibrosis should be implemented.
Our study shows that in COVID-19 ICU subject obesity is
a risk factor for unfavourable health outcomes with higher
mortality and longer hospital stay.
As the SARS-CoV-2 may continue to spread worldwide,
clinicians should maintain a high level of attention in pa-
tients with obesity. Obese subjects should be carefully
monitored and managed with a prompt and aggressive
approach in order to prevent serious and life-threatening
consequences and the increase of treatment associated costs.Declaration of Competing Interest
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